OpenAI acquires Orchestra Bio

The signal here is strategic rather than financial: OpenAI is continuing to build out through acquisition, and the target's name points to a biotech-adjacent focus, though the absence of terms, business detail or deal size leaves the actual capability being bought unclear. That opacity matters for anyone tracking how AI labs are positioning against life-sciences and RWA-adjacent data markets, since the value of such deals usually sits in proprietary data or domain expertise rather than the headline. Whether OpenAI's M&A pattern starts to cluster around specific verticals is the open question worth watching.